Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The obesity drug semaglutide may do more than shed pounds — it could also help patients struggling with eating disorders. A 60-week study found that adults on semaglutide lost nearly 15% of their body weight and showed meaningful reductions in binge eating, body dissatisfaction, and loss-of-control eating. Researchers caution, however, that ongoing monitoring of eating behaviors remains essential throughout treatment.
Semaglutide, the GLP-1 receptor agonist widely used for obesity management, may offer an unexpected bonus: meaningful improvements in eating disorder (ED) psychopathology. A new study published in the International Journal of Eating Disorders found that adults treated with semaglutide not only lost significantly more weight than those on placebo but also experienced reduced binge eating behaviors, less body dissatisfaction, and fewer loss-of-control eating episodes.
The 60-week randomized trial included 120 adults split into two groups — semaglutide (2.4 mg) or placebo — with both groups receiving dietary counseling and physical activity guidance. Semaglutide was also linked to higher rates of remission and abstinence from binge eating among participants who entered the study with a prior history of binge eating disorder.
By the Numbers:
Why it matters: These findings expand the potential therapeutic value of semaglutide beyond metabolic health, offering clinicians a new lens for treating patients with co-occurring obesity and eating disorders. Still, experts stress the importance of routinely screening for eating behaviors throughout treatment to catch any concerning changes early.